Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by M&T Bank Corp

M&T Bank Corp reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.0% during the fourth quarter, Holdings Channel.com reports. The fund owned 5,368 shares of the biopharmaceutical company’s stock after selling 112 shares during the quarter. M&T Bank Corp’s holdings in Regeneron Pharmaceuticals were worth $3,825,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of REGN. Proficio Capital Partners LLC grew its holdings in Regeneron Pharmaceuticals by 92,865.3% during the fourth quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company’s stock worth $156,284,000 after acquiring an additional 219,162 shares during the period. Worldquant Millennium Advisors LLC purchased a new position in Regeneron Pharmaceuticals in the 3rd quarter worth about $127,489,000. KBC Group NV increased its stake in Regeneron Pharmaceuticals by 296.7% in the 4th quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock worth $97,338,000 after purchasing an additional 102,198 shares in the last quarter. Icon Wealth Advisors LLC increased its stake in Regeneron Pharmaceuticals by 18,342.0% in the 3rd quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock worth $79,874,000 after purchasing an additional 75,569 shares in the last quarter. Finally, State Street Corp increased its stake in Regeneron Pharmaceuticals by 1.3% in the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after purchasing an additional 61,277 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Up 1.3 %

Shares of Regeneron Pharmaceuticals stock opened at $707.51 on Friday. The firm has a market cap of $77.35 billion, a price-to-earnings ratio of 18.48, a P/E/G ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20. The stock has a 50-day simple moving average of $696.12 and a 200-day simple moving average of $851.05.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period in the previous year, the company earned $11.86 EPS. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.50%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 2.30%.

Wall Street Analyst Weigh In

REGN has been the topic of a number of analyst reports. Robert W. Baird dropped their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 5th. Citigroup dropped their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Bank of America reissued an “underperform” rating and issued a $565.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Wells Fargo & Company dropped their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. Finally, Bernstein Bank dropped their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.